Analysis-Novartis CEO may struggle to rally investors to Sandoz spin-off
By Natalie Grover LONDON (Reuters) – Novartis CEO Vas Narasimhan could struggle to woo investors to the listing of generics drugs business Sandoz, as weaker drug prices and jittery financial…